Literature DB >> 24297035

Molecular mechanisms of [18F]fluorodeoxyglucose accumulation in liver cancer.

Kunihiko Izuishi1, Yuka Yamamoto2, Hirohito Mori3, Riko Kameyama2, Shintaro Fujihara3, Tsutomu Masaki3, Yasuyuki Suzuki1.   

Abstract

To elucidate the molecular mechanisms underlying the insufficient sensitivity in the detection of hepatocellular carcinoma (HCC) by [18F] 2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET), the characteristics of glucose metabolism-related protein expression in HCC were examined in liver metastasis from colorectal cancer (Meta). Thirty-four patients (14 Meta and 20 HCC) who underwent FDG-PET and hepatectomy were studied. The relationships between the maximum standardized uptake value (SUV) in tumors and the mRNA expression of glucose metabolism-related proteins [hexokinase (HK), glucose transporter 1 (GLUT1), and glucose-6-phosphatase (G6Pase)] and proliferating cell nuclear antigen (PCNA) were examined in snap-frozen specimens with quantitative PCR. Tumor detection rates were lower in HCC (15/20) compared to Meta (13/14) patients. HK and GLUT1 expression was lower and G6Pase expression was higher in HCC compared to Meta. In particular, GLUT1 overexpression was 92-fold in Meta and 11-fold in HCC compared to the surrounding liver. The SUV correlated with GLUT1 and PCNA expression in HCC, but not Meta patients. Of note, four cases of poorly differentiated (P/D) HCC compared to moderately differentiated (M/D) HCC produced completely different results for FDG uptake (SUV, 14.4 vs. 4.0) and mRNA expression (G6Pase expression, 0.007 vs. 1.5). Variations in the expression of glucose metabolism-related enzymes between HCC and Meta patients are attributed to origin or degree of differentiation. Low FDG uptake in M/D HCC reflected low GLUT1 and high G6Pase expression, while high FDG accumulation in P/D HCC could reflect increased GLUT1 and decreased G6Pase expression. These results may explain why M/D HCC is not detected as sensitively by FDG-PET.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24297035     DOI: 10.3892/or.2013.2886

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  20 in total

Review 1.  Functional imaging of hepatocellular carcinoma.

Authors:  Tim Ch Hoogenboom; Mark Thursz; Eric O Aboagye; Rohini Sharma
Journal:  Hepat Oncol       Date:  2016-03-29

Review 2.  The role of (18)F-FDG positron emission tomography in the follow-up of liver tumors treated with (90)Yttrium radioembolization.

Authors:  Oreste Bagni; Luca Filippi; Orazio Schillaci
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-02-15

3.  Glucose-6-phosphatase Expression-Mediated [18F]FDG Efflux in Murine Inflammation and Cancer Models.

Authors:  Mi Jeong Kim; Chul-Hee Lee; Youngeun Lee; Hyewon Youn; Keon Wook Kang; JoonHo Kwon; Abass Alavi; Sean Carlin; Gi Jeong Cheon; June-Key Chung
Journal:  Mol Imaging Biol       Date:  2019-10       Impact factor: 3.488

Review 4.  Current status of imaging biomarkers predicting the biological nature of hepatocellular carcinoma.

Authors:  Norihide Yoneda; Osamu Matsui; Satoshi Kobayashi; Azusa Kitao; Kazuto Kozaka; Dai Inoue; Kotaro Yoshida; Tetsuya Minami; Wataru Koda; Toshifumi Gabata
Journal:  Jpn J Radiol       Date:  2019-02-02       Impact factor: 2.374

Review 5.  Dysregulation of metabolic enzymes in tumor and stromal cells: Role in oncogenesis and therapeutic opportunities.

Authors:  Mohammad Aslam Khan; Haseeb Zubair; Shashi Anand; Sanjeev Kumar Srivastava; Seema Singh; Ajay Pratap Singh
Journal:  Cancer Lett       Date:  2020-01-07       Impact factor: 8.679

6.  Metformin Promotes 2-Deoxy-2-[18F]Fluoro-D-Glucose Uptake in Hepatocellular Carcinoma Cells Through FoxO1-Mediated Downregulation of Glucose-6-Phosphatase.

Authors:  Zhengjie Wang; Fei Kang; Yongheng Gao; Yi Liu; Xiaolong Xu; Xiaowei Ma; Wenhui Ma; Weidong Yang; Jing Wang
Journal:  Mol Imaging Biol       Date:  2018-06       Impact factor: 3.488

7.  18F-FDG PET/CT predicts survival after 90Y transarterial radioembolization in unresectable hepatocellular carcinoma.

Authors:  Mario Jreige; Periklis Mitsakis; Axel Van Der Gucht; Anastasia Pomoni; Marina Silva-Monteiro; Silvano Gnesin; Ariane Boubaker; Marie Nicod-Lalonde; Rafael Duran; John O Prior; Alban Denys; Niklaus Schaefer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02-23       Impact factor: 9.236

8.  Hepatocyte nuclear factor 1α-inactivated hepatocellular adenomas exhibit high (18)F-fludeoxyglucose uptake associated with glucose-6-phosphate transporter inactivation.

Authors:  Kumi Ozaki; Kenichi Harada; Noboru Terayama; Osamu Matsui; Satoshi Saitoh; Yoshito Tomimaru; Takeshi Fujii; Toshifumi Gabata
Journal:  Br J Radiol       Date:  2016-05-20       Impact factor: 3.039

Review 9.  Hyperpolarized 13C MRI: State of the Art and Future Directions.

Authors:  Zhen J Wang; Michael A Ohliger; Peder E Z Larson; Jeremy W Gordon; Robert A Bok; James Slater; Javier E Villanueva-Meyer; Christopher P Hess; John Kurhanewicz; Daniel B Vigneron
Journal:  Radiology       Date:  2019-03-05       Impact factor: 11.105

10.  68Ga-PSMA PET/CT Versus 18F-FDG PET/CT for Imaging of Hepatocellular Carcinoma

Authors:  Cihan Gündoğan; Nurhan Ergül; Mehmet Semih Çakır; Özgür Kılıçkesmez; Rıza Umar Gürsu; Tamer Aksoy; Tevfik Fikret Çermik
Journal:  Mol Imaging Radionucl Ther       Date:  2021-06-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.